Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-?) and is used to treat autoimmune diseases.
The report details the trend, potential and market size of Infliximab and biosimilar market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Infliximab and biosimilarmarket, defines the market attractiveness level of Infliximab and biosimilar market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Infliximab and biosimilar industry, describes the types of Infliximab and biosimilar market, the applications of major players and the market size, and deeply analyzes the current situation of the global Infliximab and biosimilar market and the development prospects and opportunities of Infliximab and biosimilar industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Infliximab and biosimilar market in Chapter 13.
By Player:
Janssen Biotech
Merck and Co
By Type:
Infliximab
infliximab-dyyb
infliximab-abda
By End-User:
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Infliximab and biosimilar Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Infliximab and biosimilar Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Infliximab and biosimilar Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Infliximab and biosimilar Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Infliximab and biosimilar Market Analysis and Outlook to 2022
-
7.1 Global Infliximab and biosimilar Consumption (2017-2022)
-
7.2 United States Infliximab and biosimilar Consumption (2017-2022)
-
7.3 Europe Infliximab and biosimilar Consumption (2017-2022)
-
7.4 China Infliximab and biosimilar Consumption (2017-2022)
-
7.5 Japan Infliximab and biosimilar Consumption (2017-2022)
-
7.6 India Infliximab and biosimilar Consumption (2017-2022)
-
7.7 South Korea Infliximab and biosimilar Consumption (2017-2022)
8 Region and Country-wise Infliximab and biosimilar Market Analysis and Outlook to 2028
-
8.1 Global Infliximab and biosimilar Consumption Forecast (2022-2028)
-
8.2 United States Infliximab and biosimilar Consumption Forecast (2022-2028)
-
8.3 Europe Infliximab and biosimilar Consumption Forecast (2022-2028)
-
8.4 China Infliximab and biosimilar Consumption Forecast (2022-2028)
-
8.5 Japan Infliximab and biosimilar Consumption Forecast (2022-2028)
-
8.6 India Infliximab and biosimilar Consumption Forecast (2022-2028)
-
8.7 South Korea Infliximab and biosimilar Consumption Forecast (2022-2028)
9 Global Infliximab and biosimilar Market Outlook by Types and Applications to 2022
-
9.1 Global Infliximab and biosimilar Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Infliximab Consumption and Growth Rate (2017-2022)
-
9.1.2 Global infliximab-dyyb Consumption and Growth Rate (2017-2022)
-
9.1.3 Global infliximab-abda Consumption and Growth Rate (2017-2022)
-
9.2 Global Infliximab and biosimilar Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Crohn's Disease Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Pediatric Crohn's Disease Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)
-
9.2.6 Global Psoriatic Arthritis Consumption and Growth Rate (2017-2022)
-
9.2.7 Global Plaque Psoriasis Consumption and Growth Rate (2017-2022)
10 Global Infliximab and biosimilar Market Outlook by Types and Applications to 2028
-
10.1 Global Infliximab and biosimilar Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Infliximab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global infliximab-dyyb Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global infliximab-abda Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Infliximab and biosimilar Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Pediatric Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.6 Global Psoriatic Arthritis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.7 Global Plaque Psoriasis Consumption Forecast and Growth Rate (2022-2028)
11 Global Infliximab and biosimilar Import and Export Analysis (Top 5 Countries)
-
11.1 Global Infliximab and biosimilar Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Infliximab and biosimilar Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Infliximab and biosimilar Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Infliximab and biosimilar Market Competitive Analysis
-
14.1 Janssen Biotech
-
14.1.1 Janssen Biotech Company Details
-
14.1.2 Janssen Biotech Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Janssen Biotech Infliximab and biosimilar Product and Service
-
14.2 Merck and Co
-
14.2.1 Merck and Co Company Details
-
14.2.2 Merck and Co Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Merck and Co Infliximab and biosimilar Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Infliximab and biosimilar
-
Figure Infliximab and biosimilar Picture
-
Table Global Infliximab and biosimilar Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Infliximab and biosimilar Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Infliximab and biosimilar Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Infliximab and biosimilar Consumption by Country (2017-2022)
-
Figure United States Infliximab and biosimilar Consumption and Growth Rate (2017-2022)
-
Table Europe Infliximab and biosimilar Consumption and Growth Rate (2017-2022)
-
Figure China Infliximab and biosimilar Consumption and Growth Rate (2017-2022)
-
Figure Japan Infliximab and biosimilar Consumption and Growth Rate (2017-2022)
-
Figure India Infliximab and biosimilar Consumption and Growth Rate (2017-2022)
-
Figure South Korea Infliximab and biosimilar Consumption and Growth Rate (2017-2022)
-
Figure Global Infliximab and biosimilar Consumption Forecast by Country (2022-2028)
-
Figure United States Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Infliximab and biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Infliximab Consumption and Growth Rate (2017-2022)
-
Figure Global infliximab-dyyb Consumption and Growth Rate (2017-2022)
-
Figure Global infliximab-abda Consumption and Growth Rate (2017-2022)
-
Figure Global Crohn's Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Pediatric Crohn's Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)
-
Figure Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)
-
Figure Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)
-
Figure Global Psoriatic Arthritis Consumption and Growth Rate (2017-2022)
-
Figure Global Plaque Psoriasis Consumption and Growth Rate (2017-2022)
-
Figure Global Infliximab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global infliximab-dyyb Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global infliximab-abda Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pediatric Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Psoriatic Arthritis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Plaque Psoriasis Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Infliximab and biosimilar Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Infliximab and biosimilar Export by Region (Top 5 Countries) (2017-2028)
-
Table Janssen Biotech (Foundation Year, Company Profile and etc.)
-
Table Janssen Biotech Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)
-
Table Janssen Biotech Infliximab and biosimilar Product and Service
-
Table Merck and Co (Foundation Year, Company Profile and etc.)
-
Table Merck and Co Infliximab and biosimilar Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck and Co Infliximab and biosimilar Product and Service
-
